ClicknClear Wins 2025 WIPO Global Award Honoured by the UN's Intellectual Property Agency for Innovation with Global Impact
Selected from a highly competitive pool of more than 780 applicants across 95 countries, ClicknClear was recognized for its work in solving the complex copyright challenges faced by sports and performing arts where music is used to accompany their routines - a solution that provides the content and tools needed to address copyright infringement to protect both the users of music and its creators - and for demonstrating a clear and strategic use of IP to scale its solution and contribute to addressing pressing global challenges.
"This award is more than a trophy, it's a reminder that our ideas and solutions can create real change across the world," said Chantal Epp , Founder & CEO of UK-based ClicknClear. "We're proud to be able to demonstrate that smart IP use, and doing things the right way from the outset, can fuel innovation that serves people in an impactful way."
The awards were presented during the WIPO General Assemblies at WIPO headquarters in Geneva , where over 1,400 delegates, including representatives from WIPO's 193 member states, international organizations, and innovation experts gathered to discuss the future of innovation and IP. As a winner, ClicknClear will benefit from a tailored support package that includes strategic mentoring, global visibility, and access to WIPO's international network of IP and business partners.
"The winners of the 2025 Global Awards are not just inventive, they are strategic, impact-driven, and globally minded," said Marcelo Di Pietro , Director of the WIPO Awards Program. "We're proud to support their journey."
With the visibility and support provided by the WIPO Global Awards, ClicknClear plans to further roll out and extend its solution across its partner sports and performing arts organizations. The team is currently working with lead customers to launch its next-generation technology that expands support to include the world's first blanket music licensing system for Video-on-Demand services, and welcomes collaboration opportunities with such services.
ABOUT CLICKNCLEAR
ClicknClear is an award-winning music rights tech platform delivering officially licensed music to sports that use music to accompany their routines worldwide ('choreographed sports') and performing arts for both in-person events and live-stream & video-on-demand services. Backed by music industry record labels and publishers, it is the world's first company to solve the complex music licensing issues in such uses. Its unique suite of technologies - from rights management, licensing, license verification, and Video-on-Demand support - helps address copyright infringement, protecting both the users of music and its creators.
ClicknClear works with:
event producers such as the International Olympic Committee.
sports governance organizations at international and national levels in sports and performing arts such as gymnastics, figure skating, artistic swimming, dance, dressage, jump rope, cheerleading, indoor skydiving, marching band, color guard, and show choir.
third-party and owned Video-on-Demand channels such as FloSports and sports governance organizations at international and national levels and their broadcasting partners.
https://www.clicknclear.com/
WHAT IS WIPO?
The World Intellectual Property Organization (WIPO) is the United Nations agency that serves the world's innovators and creators, ensuring that their ideas travel safely to the market and improve lives everywhere.
We do so by providing services that enable creators, innovators and entrepreneurs to protect and promote their intellectual property (IP) across borders and acting as a forum for addressing cutting-edge IP issues. Our IP data and information guide decisionmakers the world over. And our impact-driven projects and technical assistance ensure IP benefits everyone, everywhere.
https://www.wipo.int
ABOUT THE WIPO GLOBAL AWARDS
The WIPO Global Awards honor startups and small and medium-sized enterprises (SMEs) that use intellectual property (IP) as a driver for innovation, business growth, and positive social impact.
The program is organized by the World Intellectual Property Organization (WIPO), a specialized agency of the United Nations, and is part of its broader mission to foster innovation and creativity for the benefit of all.
Contact:
SOURCE ClicknClear
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Marketing Signals Unveils AI Search Optimization Service to Elevate Digital Discoverability
Online performance marketing agency Marketing Signals announces the launch of its AI Search Optimisation service, a brand new offering that's designed to help brands dominate the evolving AI-powered search landscape. As traditional SEO and paid channels adapt to the emergence of AI Overviews and large language models (LLMs), businesses must rethink their digital presence. Marketing Signals' new service integrates organic search, paid search, and the latest in AI-driven discovery to deliver a unified, future-proof strategy. An overview of the Marketing Signals AI Search Optimisation service includes: • Competitive edge in AI search: The service empowers brands to position themselves prominently within AI-generated search results by leveraging the capabilities of LLMs. • Unified search presence: Ensures consistent visibility across AI search, organic rankings, and PPC campaigns, creating a seamless brand experience. • Future-proofed SEO strategy: Adapts dynamically to changes in search algorithms and user behaviour, safeguarding visibility as AI search evolves. • Scalable, AI-led strategies: Enables low-risk testing of emerging search technologies while maintaining proven organic and paid campaign infrastructures. • Enhanced visibility & brand awareness: Targets users where they naturally discover information, whether through AI snapshots or traditional search formats. Commenting on the latest offering Gareth Hoyle, Managing Director at Marketing Signals, commented: 'AI search is not just the next phase in how users discover information; it's fundamentally changing the search landscape. Our AI Search Optimisation service equips brands to lead with visibility, adaptability and scale. By blending AI-driven tactics with trusted SEO and PPC performance, we ensure our clients are not only keeping pace, but truly ahead.' Marketing Signals encourages ambitious brands ready to explore the AI search frontier to connect and discuss how the new service can be tailored to their goals. For more information on how Marketing Signals can help your business with its AI search optimisation, you can get in touch with the team on their website. Media Contact Company Name: Marketing Signals Contact Person: Max Hammond Email: Send Email City: Manchester Country: United Kingdom Website:
National Post
2 hours ago
- National Post
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
Article content CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. ('Debiopharm'), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. Article content 'The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat solid tumors. This agreement builds upon the success of Repare and Debiopharm's existing collaboration studying the combination of lunresertib and Debio 0123,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'Our recent business development efforts have continued to enable Repare to focus on the advancement of our clinical priorities and sustained value creation. We remain focused on two ongoing Phase 1 clinical trials with readouts expected in the second half of 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor and the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor.' Article content Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. Repare and Debiopharm entered into a clinical study and collaboration agreement in January 2024 to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib. Article content 'We are excited to enter into this worldwide license agreement with Repare for lunresertib. Based on very promising Phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions,' said Bertrand Ducrey, CEO of Debiopharm. 'We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult to treat cancers.' Article content Continued Prioritization of RP-3467 and RP-1664 Article content Moving forward, Repare will remain focused on the advancement of its two ongoing Phase 1 clinical trials, POLAR and LIONS. The POLAR clinical trial is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, a small molecule inhibitor of polymerase theta (Polθ) that is a synthetic lethality target associated with BRCA mutations and other genomic alterations, alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Topline safety, tolerability and early efficacy data from the Phase 1 POLAR clinical trial of RP-3467 alone and in combination with olaparib is expected in the third quarter of 2025. The LIONS clinical trial is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664, a first-in-class, highly selective, oral inhibitor of Polo-like kinase 4 (PLK4) that is a synthetic lethality target associated with TRIM37 overexpression. Initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS clinical trial of RP-1664 is expected in the fourth quarter of 2025. Article content About Repare Therapeutics Inc. Article content Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Article content Debiopharm's Commitment to Patients Article content Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. Article content Forward-Looking Statements Article content This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of lunresertib to Debiopharm, including the potential benefits of the transaction and the achievement and receipt of milestone payments and royalties under the license agreement; the Company's anticipated cash runway; the timing, progress and results of the Company's ongoing Phase 1 LIONS and POLAR clinical trials; and the potential, tolerability, efficacy and clinical progress of the Company's product candidates, including the potential of lunresertib to treat patients with difficult-to-treat solid tumors as a monotherapy or in combination with Debio 0123. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at Article content Article content Article content Article content Article content Article content
Globe and Mail
4 hours ago
- Globe and Mail
Infrastructure: IMI CIB promotes dialogue in London on the UK's €846 billion plan
Mauro Micillo, Chief of the IMI CIB Division at Intesa Sanpaolo LONDON, July 15, 2025 (GLOBE NEWSWIRE) -- The IMI Corporate & Investment Banking Division of Intesa Sanpaolo hosted the conference 'Infrastructure and Growth Opportunities for Europe and the UK: Focus on the UK Infrastructure Strategy' in London, bringing together institutions, companies and investors to discuss the growth prospects linked to the United Kingdom's new ten-year infrastructure plan. 'Intesa Sanpaolo is playing a catalytic role in supporting investments alongside institutions, corporates, funds and investors to support the key projects of the United Kingdom's new 10-year infrastructure plan. Financing sustainable infrastructure, while supporting the so-called twin transition (green and digital), will continue to be a strategic pillar of the IMI CIB Division's strategy.' Mauro Micillo, Chief of the IMI CIB Division at Intesa Sanpaolo The United Kingdom's Plan outlines investments of more than €846 billion between 2025 and 2035, centred on three strategic pillars: infrastructure works energy transition enhancement of social and environmental systems. The Conference stems from the belief that a constructive public-private dialogue is key to accelerating projects that strengthen the competitiveness of the United Kingdom and Europe. In 2024 alone, global project finance volumes surpassed €300 billion, with transactions involving Intesa Sanpaolo's IMI CIB Division representing around €45 billion — nearly 15% of the global total. IMI Corporate & Investment Banking Division's Activities in the United Kingdom The London branch of Intesa Sanpaolo's IMI Corporate & Investment Banking Division serves as the main hub for the UK & MEA Region, which also includes operations in Dubai, Abu Dhabi, Doha, and Istanbul. In 2024, total financing volumes for corporate and financial institution clients in the Region amounted to approximately €8.5 billion (as of 31/12/2024). Since 2023, the IMI CIB Division has participated in numerous international transactions originating in the United Kingdom, supporting transition and innovation, for a total value of approximately €11 billion. Key projects supported by the IMI CIB Division include: CO₂ transport and storage – Liverpool Bay T&S. Acquisition of National Grid Transmission by Macquarie AM. Renewables and energy efficiency operations with TRIG and SEEIT. These initiatives confirm the Intesa Sanpaolo Group's ongoing commitment to enabling sustainable and digital transformation, in line with the Group's 2022–2025 Business Plan
